摘要
托伐普坦是选择性精氨酸加压素(AVP)V2受体拮抗剂,可拮抗心力衰竭时异常增多的AVP对肾脏的抗利尿作用,迅速改善心力衰竭患者的水潴留及低钠情况。应用托伐普坦发生高钠血症的可能性小,但预后差。本文重点介绍托伐普坦在治疗心力衰竭时高钠血症的发生率、危险因素、预后、预防和治疗等的国内外研究进展。
Tolvaptan is a selective arginine vasopressin(AVP)V2 receptor antagonist,which can antagonize the anti-diuretic effect of abnormally increased AVP on the kidney during heart failure,and rapidly improve the situation of water retention and low sodium in patients with heart failure.The risk of hypernatremia with tolvaptan is low,but the prognosis is poor.This article focuses on the domestic and international research progress on the incidence,risk factors,prognosis,prevention and treatment of hypernatremia in the treatment of heart failure with tolvaptan.
作者
夏月平
王倩
崔炜
Xia Yueping;Wang Qian;Cui Wei(Department of Hematology,Second Hospital of Hebei Medical University,Shijiazhuang 050000,China;The First Cardiology Department,Second Hospital of Hebei Medical University,Shijiazhuang 050000,China)
出处
《中国心血管杂志》
2020年第5期496-499,共4页
Chinese Journal of Cardiovascular Medicine
